ADVFN US – Market Content Editor
-
Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103
The pivotal study failed to show a statistically significant improvement in exercise capacity or its key secondary symptom endpoint, although prespecified subgroup and biomarker findings are prompting Tenax to pursue a revised registrational strategy with the FDA. Key Investor Takeaways Why TENX Stock Is in Focus Tenax Therapeutics (NASDAQ:TENX) reported that its 241-patient Phase 3…
-
5E Advanced Materials Secures $8 Million EXIM Investment for Fort Cady Boron Project
The federal investment supports development of Fort Cady and precedes 5E Advanced Materials’ application for a potential $285 million project debt facility as the project moves toward a Final Investment Decision. Key Investor Takeaways Why FEAM Stock Is in Focus 5E Advanced Materials (NASDAQ:FEAM) has secured an $8 million EXIM investment for its Fort Cady…
-
Varex Q3 FY2026 Results Show Revenue Growth and Margin Expansion Ahead of Teledyne Transaction
Varex Imaging reported higher revenue, stronger non-GAAP margins and improved earnings, although tariff refunds and related customer reimbursements provided a roughly $10 million benefit to quarterly gross profit. Key Investor Takeaways Why VREX Stock Is in Focus Varex Imaging (NASDAQ:VREX) reported Q3 FY2026 revenue growth alongside substantial improvement in margins and earnings, supported by continued…
-
Bowman Reports Q2 2026 Revenue Growth as Backlog Jumps 50% Ahead of $43-Per-Share Acquisition
Bowman Consulting Group delivered double-digit second-quarter growth and reaffirmed its 2026 guidance, while a separate agreement to be acquired by Bernhard Capital Partners shifts investor attention toward the pending all-cash transaction. Key Investor Takeaways Why BWMN Stock Is in Focus Bowman Consulting Group (NASDAQ:BWMN) reported strong Q2 2026 revenue growth and a sharply higher backlog…
-
Socket Mobile Expands Industrial Mobility Distribution Through 3Eye Technologies Partnership
The agreement gives Socket Mobile broader access to North American mobility resellers as it targets Apple-based data capture deployments across frontline and industrial operations. Key Investor Takeaways Why SCKT Stock Is in Focus Socket Mobile (NASDAQ:SCKT) is expanding its industrial mobility distribution strategy through a new partnership with 3Eye Technologies, a value-added distributor focused on…
-
Medical Care Technologies Expands StrainScan Pro Into Agricultural Quality Control for iPad Air
StrainScan Pro is being positioned for portable enterprise use across farming and post-harvest operations as Medical Care Technologies targets agricultural applications for its proprietary AI vision technology. Key Investor Takeaways Why MDCE Stock Is in Focus Medical Care Technologies (USOTC:MDCE) is expanding StrainScan Pro into agricultural quality control, positioning its proprietary AI vision software for…
-
Bristol Myers Squibb plans $2.3 billion Houston manufacturing campus
Bristol Myers Squibb (NYSE:BMY) has unveiled plans to invest approximately $2.3 billion in a new manufacturing campus at Generation Park in Houston, Texas, as the pharmaceutical group expands its production capabilities in the United States. The project is expected to create nearly 500 permanent skilled positions alongside approximately 2,000 construction and other indirect jobs between…
-
Silicon Motion shares slide 8% after unveiling $800 million convertible notes offering
Silicon Motion Technology (NASDAQ:SIMO) shares fell 7.9% in pre-market trading on Monday after the NAND flash controller specialist announced plans to raise $800 million through an offering of convertible senior notes due in 2031. The proposed financing will be conducted through a private placement to qualified institutional buyers under Rule 144A of the Securities Act.…
-
Aquestive Therapeutics shares jump after encouraging Anaphylm study results
Aquestive Therapeutics (NASDAQ:AQST) shares rose 9.5% on Monday after the pharmaceutical company reported positive human factors and pharmacokinetic study results for Anaphylm, strengthening its preparations to resubmit a New Drug Application to the U.S. Food and Drug Administration. The studies evaluated Anaphylm (dibutepinephrine) sublingual film and were designed to address issues raised by regulators during…
-
Ryman Hospitality shares fall after launching 5.1 million-share offering
Ryman Hospitality Properties (NYSE:RHP) shares fell 3.3% in pre-market trading on Monday after the company launched an underwritten public offering of 5.1 million common shares to help finance its planned acquisition of two major Orlando resort properties. The company intends to use the net proceeds from the equity raise to fund part of the approximately…